Gastrointestinal Stromal Tumors of the Stomach and Esophagus

Area of Science:

• Oncology
• Gastroenterology

Background:

• Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms originating in the gastrointestinal (GI) tract.
• Mutations in c-kit or PDGFRA proto-oncogenes are the primary drivers of GIST development.
• Surgical resection remains a cornerstone of GIST management.

Purpose of the Study:

• To review the role of molecular profiling in guiding treatment strategies for GISTs.
• To discuss the efficacy of imatinib in neoadjuvant and adjuvant settings for GIST patients.
• To emphasize the importance of interval imaging and surveillance in GIST management.

Main Methods:

• Review of existing literature on GIST treatment modalities.
• Analysis of studies investigating molecular alterations in GISTs.
• Evaluation of clinical trial data for imatinib therapy in GIST.

Main Results:

• Molecular profiling offers critical insights into personalized GIST treatment.
• Imatinib demonstrates significant clinical benefit in both neoadjuvant and adjuvant settings for GIST.
• Adherence to national surveillance guidelines and regular imaging is crucial for GIST patient care.

Conclusions:

• Multidisciplinary management integrating surgery, molecular profiling, and targeted therapy optimizes GIST outcomes.
• Imatinib therapy is a key component of modern GIST treatment paradigms.
• Long-term surveillance following treatment is essential for monitoring GIST recurrence and patient survival.